| Brandon Lampe, DPM | |
|
1675 Republic Pkwy Ste 101, Mesquite, TX 75150-6902 | |
| (972) 270-7627 | |
| Not Available |
| Full Name | Brandon Lampe |
|---|---|
| Gender | Male |
| Speciality | Podiatry |
| Experience | 7 Years |
| Location | 1675 Republic Pkwy Ste 101, Mesquite, Texas |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1649647124 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 213E00000X | Podiatrist | 2267 (Texas) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Methodist Dallas Medical Center | Dallas, TX | Hospital |
| Provider Name | Interventional Partners Pllc |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1750814737 PECOS PAC ID: 6800173204 Enrollment ID: O20170512002018 |
News Archive
Ensuring that people with preexisting health conditions can get and keep health insurance is the most popular part of the Affordable Care Act. It has also become a flashpoint in this fall's campaigns across the country.
Developing radical new strategies and technologies to detect cancer at its earliest stage is the bold ambition of a new transatlantic research alliance, announced today (Monday) by Cancer Research UK and partners.
BioPontis Alliance, LLC announced today that it has entered into an innovative strategic agreement with Merck (known outside the US and Canada as MSD) designed to bridge the gap between early academic discovery science and the development of medicines and technologies that impact human health. The announcement was made this week at the prestigious Partnering For Cures Conference that is convened annually for the purpose of forging strategic cross-sector collaborations.
Imprimis Pharmaceuticals, Inc., a pharmaceutical company focused on the development and commercialization of proprietary compounded drug formulations, today announced it now has the exclusive US commercial rights to the patented compounded alkalinized lidocaine and heparin formulation ("Hep-Lido-A" or "HLA") for the treatment of interstitial cystitis ("IC"), commonly referred to as painful bladder syndrome ("PBS").
Felipe P-triz, Secretary of State for Research and Emilio Bot-n, President of the Grupo Santander, signed today a milestone agreement giving birth to the PESA (Progression of Early Subclinical Atherosclerosis) CNIC-Santander trial. The project's main goal is to increase the knowledge about cardiovascular diseases.
› Verified 2 days ago
| Provider Name | Foot & Ankle Center Of Dallas Pllc |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1861133290 PECOS PAC ID: 1557758943 Enrollment ID: O20220504001278 |
News Archive
Ensuring that people with preexisting health conditions can get and keep health insurance is the most popular part of the Affordable Care Act. It has also become a flashpoint in this fall's campaigns across the country.
Developing radical new strategies and technologies to detect cancer at its earliest stage is the bold ambition of a new transatlantic research alliance, announced today (Monday) by Cancer Research UK and partners.
BioPontis Alliance, LLC announced today that it has entered into an innovative strategic agreement with Merck (known outside the US and Canada as MSD) designed to bridge the gap between early academic discovery science and the development of medicines and technologies that impact human health. The announcement was made this week at the prestigious Partnering For Cures Conference that is convened annually for the purpose of forging strategic cross-sector collaborations.
Imprimis Pharmaceuticals, Inc., a pharmaceutical company focused on the development and commercialization of proprietary compounded drug formulations, today announced it now has the exclusive US commercial rights to the patented compounded alkalinized lidocaine and heparin formulation ("Hep-Lido-A" or "HLA") for the treatment of interstitial cystitis ("IC"), commonly referred to as painful bladder syndrome ("PBS").
Felipe P-triz, Secretary of State for Research and Emilio Bot-n, President of the Grupo Santander, signed today a milestone agreement giving birth to the PESA (Progression of Early Subclinical Atherosclerosis) CNIC-Santander trial. The project's main goal is to increase the knowledge about cardiovascular diseases.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Brandon Lampe, DPM 1675 Republic Pkwy, Ste 101, Mesquite, TX 75150-6902 Ph: (972) 270-7627 | Brandon Lampe, DPM 1675 Republic Pkwy Ste 101, Mesquite, TX 75150-6902 Ph: (972) 270-7627 |
News Archive
Ensuring that people with preexisting health conditions can get and keep health insurance is the most popular part of the Affordable Care Act. It has also become a flashpoint in this fall's campaigns across the country.
Developing radical new strategies and technologies to detect cancer at its earliest stage is the bold ambition of a new transatlantic research alliance, announced today (Monday) by Cancer Research UK and partners.
BioPontis Alliance, LLC announced today that it has entered into an innovative strategic agreement with Merck (known outside the US and Canada as MSD) designed to bridge the gap between early academic discovery science and the development of medicines and technologies that impact human health. The announcement was made this week at the prestigious Partnering For Cures Conference that is convened annually for the purpose of forging strategic cross-sector collaborations.
Imprimis Pharmaceuticals, Inc., a pharmaceutical company focused on the development and commercialization of proprietary compounded drug formulations, today announced it now has the exclusive US commercial rights to the patented compounded alkalinized lidocaine and heparin formulation ("Hep-Lido-A" or "HLA") for the treatment of interstitial cystitis ("IC"), commonly referred to as painful bladder syndrome ("PBS").
Felipe P-triz, Secretary of State for Research and Emilio Bot-n, President of the Grupo Santander, signed today a milestone agreement giving birth to the PESA (Progression of Early Subclinical Atherosclerosis) CNIC-Santander trial. The project's main goal is to increase the knowledge about cardiovascular diseases.
› Verified 2 days ago
Michael Birau, DPM Podiatrist Medicare: Accepting Medicare Assignments Practice Location: 1601 N Belt Line Rd Ste A, Mesquite, TX 75149 Phone: 972-288-7441 Fax: 833-916-2197 | |
Rebekah Cherian, D.P.M. Podiatrist Medicare: Medicare Enrolled Practice Location: 1601 N Belt Line Rd Ste A, Mesquite, TX 75149 Phone: 972-288-7442 | |
Dr. William C Arrington Ii, DPM Podiatrist Medicare: Accepting Medicare Assignments Practice Location: 1601 N Belt Line Rd, Suite A, Mesquite, TX 75149 Phone: 972-288-7441 Fax: 972-289-8025 | |
Interventional Partners Pllc Podiatrist Medicare: Medicare Enrolled Practice Location: 1601 N Belt Line Rd Ste A, Mesquite, TX 75149 Phone: 972-288-7441 Fax: 972-289-8025 | |
Robert A. Young Podiatrist Medicare: Not Enrolled in Medicare Practice Location: 1336 N Galloway Ave, Suite 124, Mesquite, TX 75149 Phone: 972-288-7441 Fax: 972-289-8025 | |
Motion Foot & Ankle Institute Podiatrist Medicare: Medicare Enrolled Practice Location: 1320 N Galloway Ave Ste 105, Mesquite, TX 75149 Phone: 214-550-2099 Fax: 214-550-2099 | |
Michael Jan Miller, D.P.M. Podiatrist Medicare: Accepting Medicare Assignments Practice Location: 1675 Republic Pkwy, Suite 101, Mesquite, TX 75150 Phone: 972-270-7627 Fax: 972-270-7759 |